694 related articles for article (PubMed ID: 23777987)
1. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.
Jacobson PA; Green K; Birnbaum A; Remmel RP
Cancer Chemother Pharmacol; 2002 Jun; 49(6):461-7. PubMed ID: 12107550
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes.
Bae SK; Cao S; Seo KA; Kim H; Kim MJ; Shon JH; Liu KH; Zhou HH; Shin JG
Drug Metab Dispos; 2008 Aug; 36(8):1679-88. PubMed ID: 18474675
[TBL] [Abstract][Full Text] [Related]
4. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism.
Rae JM; Soukhova NV; Flockhart DA; Desta Z
Drug Metab Dispos; 2002 May; 30(5):525-30. PubMed ID: 11950782
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
Turpeinen M; Nieminen R; Juntunen T; Taavitsainen P; Raunio H; Pelkonen O
Drug Metab Dispos; 2004 Jun; 32(6):626-31. PubMed ID: 15155554
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes.
Cho DY; Bae SH; Lee JK; Kim YW; Kim BT; Bae SK
Drug Metab Dispos; 2014 Jan; 42(1):33-9. PubMed ID: 24167220
[TBL] [Abstract][Full Text] [Related]
7. Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes.
Misaka S; Kawabe K; Onoue S; Werba JP; Giroli M; Tamaki S; Kan T; Kimura J; Watanabe H; Yamada S
Drug Metab Pharmacokinet; 2013; 28(3):244-9. PubMed ID: 23268924
[TBL] [Abstract][Full Text] [Related]
8. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro.
Chang SY; Chen C; Yang Z; Rodrigues AD
Drug Metab Dispos; 2009 Aug; 37(8):1667-75. PubMed ID: 19454483
[TBL] [Abstract][Full Text] [Related]
9. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
10. Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes.
Cai X; Wang RW; Edom RW; Evans DC; Shou M; Rodrigues AD; Liu W; Dean DC; Baillie TA
Drug Metab Dispos; 2004 Jun; 32(6):584-6. PubMed ID: 15155548
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
12. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.
Chang Y; Fang WB; Lin SN; Moody DE
Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):55-62. PubMed ID: 20825389
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms.
Lee HK; Moon JK; Chang CH; Choi H; Park HW; Park BS; Lee HS; Hwang EC; Lee YD; Liu KH; Kim JH
Drug Metab Dispos; 2006 Jul; 34(7):1090-5. PubMed ID: 16581944
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.
Court MH; Duan SX; Hesse LM; Venkatakrishnan K; Greenblatt DJ
Anesthesiology; 2001 Jan; 94(1):110-9. PubMed ID: 11135730
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
16. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
Heyn H; White RB; Stevens JC
Drug Metab Dispos; 1996 Sep; 24(9):948-54. PubMed ID: 8886603
[TBL] [Abstract][Full Text] [Related]
17. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
Richter T; Mürdter TE; Heinkele G; Pleiss J; Tatzel S; Schwab M; Eichelbaum M; Zanger UM
J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
[TBL] [Abstract][Full Text] [Related]
18. Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6.
Bhateria M; Ramakrishna R; Puttrevu SK; Saxena AK; Bhatta RS
Chem Biol Interact; 2016 Aug; 256():257-65. PubMed ID: 27387538
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions.
Micuda S; Mundlova L; Anzenbacherova E; Anzenbacher P; Chladek J; Fuksa L; Martinkova J
Eur J Clin Pharmacol; 2004 Oct; 60(8):583-9. PubMed ID: 15378224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
